In this episode, we discuss with Dr. Martin Kaiser how to identify and manage newly diagnosed high-risk multiple myeloma in the current era of effective frontline therapies. Here are the key studies that we touched upon:1. Phase II OPTIMUM (MUKnine) trial in ultra-high-risk myeloma and PCL:https://pubmed.ncbi.nlm.nih.gov/37315268/ 2. Meta-analysis of >2500 patients with chromosome 1q21 abnormalities:https://pubmed.ncbi.nlm.nih.gov/34092058/ 3. Predicting ultra-high risk myeloma by molecular profiling (including SKY92 GEP signature):https://pubmed.ncbi.nlm.nih.gov/32157174/ 4. French data on adverse prognostic impact of del(1p32):https://pubmed.ncbi.nlm.nih.gov/36375118/ 5. S1211 study: The first high-risk enrichment RCT in myeloma (VRD vs Elo-VRD):https://pubmed.ncbi.nlm.nih.gov/33357482/ 6. Outcome of “double-hit” patients in MASTER and Dara-VRD arm of GRIFFIN trial:https://ashpublications.org/blood/article/140/Supplement%201/10144/488521 7. Impact of Auto-Transplant on decreasing MRD burden in high-risk myeloma (including double-hits):https://pubmed.ncbi.nlm.nih.gov/35731911/8. Preliminary results from GMMG-CONCEPT trial in high-risk myeloma:https://pubmed.ncbi.nlm.nih.gov/34732857/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related